Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HOOIP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
39298786 ADC2 (DAR4)
|
|||||
| Synonyms |
ADC2 (DAR4)
Click to Show/Hide
|
|||||
| Organization |
Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
AZ14170132
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Val-Ala-PEG8
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||